Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adavosertib Plus Chemotherapy in Platinum-Resistant Ovarian Cancer
NCT02272790Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2015
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of adavosertib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (5 arms), sponsored by AstraZeneca. Primary endpoint: Objective Response Rate up to 19 months. Started Jan 2015; status: completed.
02
Drugs
adavosertib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02272790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02272790.